Literature DB >> 34061581

Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic).

Jesper Jensen1,2, Massar Omar3,4, Caroline Kistorp5,2, Christian Tuxen6, Ida Gustafsson6, Lars Køber7,2, Finn Gustafsson7,2, Jens Faber8,2, Julie L Forman9, Jacob E Møller3,7,10, Morten Schou1,2,10.   

Abstract

Entities:  

Keywords:  body composition; diabetes mellitus, type 2; empagliflozin; heart failure; insulin resistance; sodium-glucose transporter 2 inhibitors

Mesh：

Substances：

Year:  2021        PMID： 34061581     DOI： 10.1161/CIRCULATIONAHA.120.053463

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  3 in total

Review 1.  Empagliflozin for Patients with Heart Failure and Type 2 Diabetes Mellitus: Clinical Evidence in Comparison with Other Sodium-Glucose Co-transporter-2 Inhibitors and Potential Mechanism.

Authors:  Bo Liang; Rui Li; Peng Zhang; Ning Gu
Journal:  J Cardiovasc Transl Res       Date:  2022-08-15       Impact factor: 3.216

2.  The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker).

Authors:  Massar Omar; Jesper Jensen; Caroline Kistorp; Kurt Højlund; Lars Videbæk; Christian Tuxen; Julie H Larsen; Camilla F Andersen; Finn Gustafsson; Lars Køber; Morten Schou; Jacob Eifer Møller
Journal:  Cardiovasc Diabetol       Date:  2022-02-27       Impact factor: 9.951

3.  Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial.

Authors:  Atsushi Tanaka; Takumi Imai; Michio Shimabukuro; Isao Taguchi; Akira Sezai; Shigeru Toyoda; Hirotaka Watada; Junya Ako; Koichi Node
Journal:  Cardiovasc Diabetol       Date:  2022-08-08       Impact factor: 8.949
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.